Good Morning,
Welcome to this week’s edition of biotechnological marvels and breakthroughs, illuminating the audacious strides humanity is taking to redefine its very existence.
From Silicon Valley’s relentless quest for immortality to the profound intricacies of our genetic code, and the revolutionary realm of brain-computer interfacing, this newsletter presents a panorama of where science meets ambition. Each piece in today’s collection underscores a commitment to push boundaries, both ethically and scientifically, all in the pursuit of a brighter, longer-lived future for humanity.
Let’s unfold the next big opportunity…
Silicon Valley Ventures into Longevity (BBC)
Silicon Valley’s elite are diving deep into the pursuit of immortality, as highlighted by BBC Radio 4’s podcast, The Immortals, hosted by Aleks Krotoski. From the audacious experiment of connecting young and old mice to study rejuvenating effects of young blood to tech entrepreneur Bryan Johnson’s trials with youthful blood plasma transfusions, the boundaries are continually being pushed.
Moreover, biotech entrepreneur Celine Halioua is innovatively targeting the anti-ageing quest by testing potential drugs on dogs, while cryptocurrency guru Vitalik Buterin experiments with an entire ‘longevity state’. The final frontier? Transhumanists like Bryan Johnson merging humans with technology, envisioning a future where we may cheat death.
The Rise of Genome Sequencing (Wired)
DNA sequencing’s popularity is growing as a means to assess risk for certain diseases and potentially offer personalized medicines.
In London, Genomics England encourages the public to participate in genome sequencing, an initiative where participants provide blood samples for DNA readout, aiding in research for better treatments. Anyone over 18 in the UK can sign up, with similar projects in other countries. While commercial tests, like 23andMe, analyze specific genetic markers, whole-genome sequencing delves deeper, revealing one’s entire DNA. Despite the promise of this technology, concerns over data storage and privacy persist. As genomics evolves, experts envision its use in pharmacogenetics, tailoring drug prescriptions to individuals’ genetic makeup.
Musk’s Vision of Brain-Computer Integration Inches Closer (Washington Post)
Neuralink, Elon Musk’s brain-tech venture, has obtained U.S. FDA clearance to commence its inaugural human trials of an innovative brain-implant device. Historically, research had only been conducted on animals. This device, surgically placed within the brain, will decode neural activities for computer interfacing.
While companies like Blackrock Neurotech have ventured into this space, primarily targeting medical ailments, Neuralink’s vision extends to enhancing human capabilities. Some controversies surround Neuralink’s methods, especially their animal research. There’s no definite timeline for these clinical trials, but they align with Musk’s other ventures spanning electric cars, rockets, AI, and his recent acquisition of Twitter..
Navigating the nuanced tapestry of biotechnology, one thing becomes clear: the frontier of human progress is vast and rapidly evolving. This week, we’ve glimpsed Silicon Valley’s daring experiments, peered into the depths of our genetic heritage, and watched the merger of mind and machine inch closer to reality. It’s a testament to human ingenuity and the boundless potential of collaboration across various disciplines.
To a future where science, ethics, and the human spirit intertwine in the quest for understanding and progress.
Until next time,
The Longr Reads Team
“In the end, it’s not the years in your life that count. It’s the life in your years.”
Abraham Lincoln, US President
Longr Reads’ of the Week
- ‘We have to invest much more in our future selves’ (Financial Times)
- Inside one of Europe’s first longevity clinics (Sifted)
- Are you ready for the “Longevity Economy”? (Stanford Business School)
